http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002045186-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2001-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9bfcb523b64cb10a4530710097339e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29591c1476182bd532b1a96c03b40488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77d955137f2e0021b33f46491528687 |
| publicationDate | 2002-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002045186-A1 |
| titleOfInvention | Inhibition of protein binding to mast cells |
| abstract | The invention relates to a compound inhibiting the binding of the free light chain of immunoglobin (Ig LC) to mast cells. It has been found that Ig LC is the agent responsible for the sensitization of mast cells. The compounds according to the invention can thus be used for the preparation of a drug for the treatment of a disease whose symptom is an elevated Ig LC concentration in serum or spinal fluid. The invention also relates to a method of screening a series of compounds on their ability to reduce the sensitization of mast cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005191290-A1 |
| priorityDate | 1998-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.